Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Skin Neoplasms 1Plasmablastic Lymphoma 1Oligodendroglioma 1Melanoma 1Lymphomatoid Granulomatosis 1Lymphoma, Primary Effusion 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lung Neoplasms 1Glioma 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Astrocytoma 1

Interventions

Temozolomide 29Bevacizumab 15Radiotherapy 13antineoplaston AS 2-1 8antineoplaston A10 8Everolimus 7Radiation 6Erlotinib Hydrochloride 6Radiotherapy, Intensity-Modulated 5Lomustine 4veliparib 3palbociclib 3Vorinostat 3Sunitinib 3Radiotherapy, Conformal 3Magnetic Resonance Spectroscopy 3Carmustine 3Carboplatin 3temsirolimus 2selinexor 2poly ICLC 2etoposide phosphate 2cabozantinib 2Sirolimus 2Nivolumab 2Irinotecan 2Immunoglobulin G 2Imatinib Mesylate 2Etoposide 2Donepezil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Astrocytoma × varlilumab × Clear all
NCT02924038 2024-06-14

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

University of California, San Francisco

Phase 1 Terminated
14 enrolled 10 charts
CNSLymphoid

Astrocytoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡